Phase 3 N=7 Treatment

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Alagille Syndrome (ALGS)

Bottom Line

View on ClinicalTrials.gov: NCT05543174 ↗

Enrolled (actual)

Serious AEs

14.3%

Results posted

Oct 2024

Primary outcome: Primary: Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22 — 17.643 micromoles per liter (mcmol/L)

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: TAK-625 (Drug)
Age: Pediatric, Adult, Older Adult · 0+ yrs
Sex: All
Sponsor: Takeda
Primary completion: Oct 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22	17.643	—
SECONDARY Change in Fasting sBA Levels From Baseline to Week 18	8.300	—
SECONDARY Change in Weekly Average Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18	-1.531	—
SECONDARY Change in Weekly Average Morning Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18	-1.327	—
SECONDARY Change in Weekly Average Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22	-0.286	—
SECONDARY Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22	-0.280	—
SECONDARY Change in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18	-1.381	—
SECONDARY Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18	-1.238	—
SECONDARY Change in Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels From Baseline to Week 18	17.7; 75.6	—
SECONDARY Change in Bilirubin (Total and Direct) Levels From Baseline to Week 18	11.3619; 8.6009	—
SECONDARY Change in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22	0.000	—
SECONDARY Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22	-0.032	—
SECONDARY Change in ALT and ALP Levels From Week 18 to 22	7.9; -32.3	—
SECONDARY Change in Bilirubin (Total and Direct) Levels From Week 18 to 22	0.6842; 1.2217	—

Summary

The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future. The participants will be treated with TAK-625 for up to the end of study (about 34 months). Participants will visit their study clinic 9 times from the start of study. After 9 times visits, participants will visit their study clinic every 12 weeks up to the end of study.

Eligibility Criteria

Inclusion Criteria

The participant is Japanese male or female with a body weight >=3.0 kilograms (kg) and who is >=1 month of age at the time of informed consent.
The participant is diagnosed with ALGS.
The participant has one or more of the following evidences of cholestasis:
Total serum bile acid (sBA) >3^ upper limit of the normal range (ULN) for age.
Direct bilirubin (conjugated) >1 mg/dL.
Lipid soluble vitamin (LSV) deficiency otherwise unexplainable.
Gamma-glutamyl transferase (GGT) >3^ ULN for age.
Intractable pruritus explainable only by liver disease.
The participant is expected to have a consistent caregiver(s) for the duration of the study.
The participant has an access to phone for scheduled calls from study site.
Both a caregiver and participant above the age of assent are capable of reading and understanding the questionnaires.
Caregivers (and age-appropriate participants) must be willing and able to use an eDiary device during the study.
Caregivers (and age-appropriate participants) must complete at least 10 eDiary reports (morning or evening) during each of 2 consecutive weeks of the screening period (maximum possible reports=14 per week), even if the participant is an adult (over 18 years old).
Average daily score >2 on the ItchRO questionnaire (maximum possible daily score of 4) for 2 consecutive weeks in the screening period, prior to dosing. A daily score is the higher of the scores for the morning and evening ItchRO. The average daily score is the sum of all daily scores divided by the number of days the ItchRO was completed. Since it is difficult to evaluate pruritus in infants, participants 15^ ULN, international normalized ratio [INR] >1.5 [unresponsive to vitamin K therapy], albumin <3.0 g/dL, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy).
The participant has a history or presence of other concomitant liver disease.
The participant has a history or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease).
The participant has a history or presence of gallstones or kidney stones.
The participant has a possible malignant liver mass in imaging, including screening ultrasound.
The participant has cancers, except for in situ carcinoma, or cancers treated at least 5 years prior to screening with no evidence of recurrence.
The participant has received bile acid/lipid binding resins or IBAT inhibitors within 28 days prior to screening and throughout the trial.
The participant who has received sodium phenylbutyrate for less than 6 months at the initiation of screening.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05543174). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.